Lenskart IPO Day 2 Subscription Status: Check Full Subscription Data, GMP Trend, Should You Apply or Not
Lenskart IPO Day 2 Subscription Status: The Lenskart IPO Day 2 subscription status is making waves on Dalal Street locks in a price band of ₹ 382–402 per share and targets a post-issue market cap near ₹ 70,000 crore. With a fresh issue of ~₹ 2,150 crore and an OFS of ~₹ 5,128 crore, the eyewear major has ignited the investor buzz.

This article breaks down what you need to know—Lenskart IPO Day 2 subscription status, grey market premium (GMP) and IPO review —with data that matters for Indian retail and institutional investors alike.
What is the Lenskart IPO Day 2 Subscription Status?
The Lenskart IPO Day 2 subscription status has seen solid traction across investor categories, with crossing 2 times overall. Retail participation has been particularly enthusiastic, highlighting strong investor confidence in the eyewear giant’s business model despite its steep valuation.
Lenskart IPO Day 1 Subscription Status & Lenskart IPO Day 2 Subscription Status
(as per NSE data)
| Category | Day 1 (Nov 1, 2025) | Day 2 (Nov 3, 2025) | Trend |
|---|---|---|---|
| Qualified Institutional Buyers (QIB) | 1.42× | 1.64× | 🔼 Increasing |
| Non-Institutional Investors (NII/HNI) | 0.41× | 1.89× | 🔼 Strong Jump |
| Retail Individual Investors (RII) | 1.31× | 3.33× | 🔼 Heavy Demand |
| Employee Category | — | 2.62× | 🔼 Robust Interest |
| Overall Subscription | 1.13× | 2.02× | 🔼 Steady Build-Up |
What Does Lenskart IPO Day 2 Subscription StatusData Indicate?
The Lenskart IPO Day 2 Subscription Status & Day 1 pattern suggests that institutional investors are steadily increasing bids, while retail investors have already oversubscribed their quota by more than 3×. This indicates a strong sentiment on Dalal Street — even as analysts flag that the Lenskart IPO’s high valuation may limit post-listing upside.
The rising NII participation also hints that HNI investors expect near-term listing gains, backed by a GMP of around ₹70, signalling potential 18% upside on debut.
What is Lenskart IPO GMP Today (Grey market movement)?
The GMP ~₹70 points to a ~18% expected listing gain. GMP signals how secondary market participants view the listing risk-reward.
Should you apply? Key questions for Indian investors
Before you hit “apply”, ask: Does the high valuation still leave scope for listing gain and long-term value? Here are major considerations:
1. Margin & Profitability Risk:
Lenskart’s profitability is new but margins stay tight due to heavy spends on expansion, tech, and marketing.
2. Valuation Comfort & Growth Drivers:
A ₹70,000 crore valuation sets high growth expectations, leaving little room for error amid rising competition and costs.
3.Macro/Sector Outlook:
India’s retail-tech and vision care sectors support Lenskart’s growth, though global volatility may temper investor appetite.
4.Allocation Strategy:
Apply selectively; limit exposure, track listing risks, and align investment with your risk tolerance and exit plan.
Conclusion & Takeaway
The Lenskart IPO Day 2 subscription status signals a landmark moment for Indian organised retail and omni-channel business. For those keen on Dalal Street action, the listing offers potential double‐digit listing gains as reflected by GMP.
Key takeaways:
- The business strength is meaningful: diversified presence, profitability transition and investor support.
- The valuation requires sustained outperformance; if growth slows, margin slips or macro turns adverse, the risk‐reward narrows.
- For Indian investors: treat this IPO as opportunity plus risk. If you believe in Lenskart’s growth beyond the listing euphoria, and are comfortable with higher risk, an application may make sense. Otherwise, waiting for post‐listing price performance might be prudent.
In short: apply, but apply wisely — size appropriately, set expectations realistic, and keep an eye on performance metrics post‐listing.
Click Here to know more market & IPO related news and updates.
Disclaimer: The views and investment insights provided here are based on publicly available information and do not constitute financial advice. Readers are advised to conduct their own research or consult certified financial experts before making investment decisions.



